Enimmune Corporation (TPEX:6564)

Enimmune Revenue

Enimmune had revenue of 27.90M TWD in the half year ending June 30, 2026, with 37.26% growth. This brings the company's revenue in the last twelve months to 53.45M, up 26.56% year-over-year. In the year 2025, Enimmune had annual revenue of 48.19M with 20.74% growth.

• Revenue (ttm): 53.45M
• Revenue Growth: +26.56%
• P/S Ratio: 21.73
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 1.16B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	48.19M	8.28M	20.74%
Dec 31, 2024	39.92M	-3.58M	-8.23%
Dec 31, 2023	43.49M	-144.92M	-76.92%
Dec 31, 2022	188.42M	78.59M	71.56%
Dec 31, 2021	109.82M	86.95M	380.08%

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 26, 2026

Data Sources Report a data error